Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Haemonetics' John White

This article was originally published in The Gray Sheet

Executive Summary

Haemonetics' John White: Chairman and CEO steps down Jan. 27 at the request of the board of directors, which cites a leveling off in the blood products and processing systems maker's financial performance over the last two years. White is succeeded as CEO by James Peterson, formerly vice chairman and president of Haemonetics International. Succeeding White as chairman is Sir Stuart Burgess, who has been a board member since 1992 and is former CEO of Amersham International. White, who had been CEO since 1985, "helped to grow the company from a $32 mil. business to a global firm with over $300 mil. in revenues," the firm notes. For the three months ended Dec. 27, net revenues decreased 1% to $75.8 mil. Excluding the effect of a $25.2 mil. restructuring charge, net income declined 33% to $4.7 mil...

You may also be interested in...

Post-Brexit MHRA Will Embrace Medtech ‘Innovation Pull’ In The UK

The national regulator is to undergo a review in 2021 as the UK begins life as a former EU member, presenting opportunities to be seized.

QUOTED. 26 November 2020. Rachel Nuzum.

Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.

China Poised To Conditionally Approve First COVID Vaccine

The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts